

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/556,224 |
| Filing Date | September 27, 2006 |
| First Named Inventor | Martin Hendrix et al. |
| Art Unit | 1624 |
| Examiner Name | Susanna Moore |
| Attorney Docket Number | 01-2116 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. | Document Number Number - Kind Code* (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------|-----------------|---|--------------------------------|--|---|
| A1 | US- 5 041 449 | | 08-20-1991 | BELLEAU ET AL. | |
| A2 | US- 5 047 407 | | 09-10-1991 | BELLEAU ET AL. | |
| A3 | US- 5 270 315 | | 12-14-1993 | BELLEAU ET AL. | |
| A4 | US- 5 294 612 | | 03-15-1994 | BACON ET AL. | |
| A5 | US- 5 466 806 | | 11-14-1995 | BELLEAU ET AL. | |
| A6 | US- 5 541 187 | | 07-30-1996 | BACON ET AL. | |
| A7 | US- 5 563 049 | | 10-08-1996 | KOJIMA ET AL. | |
| A8 | US- 5 684 164 | | 11-04-1997 | BELLEAU ET AL. | |
| A9 | US- 5 750 673 | | 05-12-1998 | MARTIN PIERRE | |
| A10 | US- 5 053 499 | | 10-01-1999 | KOJIMA ET AL. | |
| A11 | US- 5 969 116 | | 10-19-1999 | MARTIN, PIERRE | |
| A12 | US- 5 977 332 | | 11-02-1999 | MARTIN, PIERRE | |
| A13 | US- 5 977 118 | | 11-02-1999 | BACON ET AL. | |
| A14 | US- 6 100 037 | | 08-08-2000 | PHILLIPS ET AL. | |
| A15 | US- 6 175 008 | | 01-16-2001 | BELLEAU ET AL. | |
| A16 | US- 6 174 884 | | 01-16-2001 | HANING ET AL. | |
| A17 | US- 6 211 158 | | 04-03-2001 | SEELA ET AL. | |
| A18 | US- 6 831 174 | | 11-15-2001 | BELLEAU ET AL. | |
| A19 | US- 2001 041797 | | 11-15-2001 | BELLEAU ET AL. | |
| A20 | US- 6 350 753 | | 02-26-2002 | BELLEAU ET AL. | |
| A21 | US- 2002 058635 | | 05-16-2002 | AYERETT, DEVRON R. | |
| A22 | US- 6 458 796 | | 10-01-2002 | HANING ET AL. | |
| A23 | US- 6 479 463 | | 11-12-2002 | WANG ET AL. | |
| A24 | US- 2003 087918 | | 05-08-2003 | BELLEAU ET AL. | |
| A25 | US- 6 903 224 | | 05-08-2003 | BELLEAU ET AL. | |
| A26 | US- 7 057 507 | | 12-25-2003 | PULLEY ET AL. | |
| A27 | US- 2004 185459 | | 09-23-2004 | OTSUKA ET AL. | |
| A28 | US- 2004 220186 | | 11-04-2004 | BELL ET AL. | |
| A29 | US- 2004 254201 | | 12-16-2004 | BELLEAU ET AL. | |
| A30 | US- 7 122 693 | | 12-16-2004 | BELLEAU ET AL. | |
| A31 | US-2005 209251 | | 09-22-2005 | LINKER ET AL. | |
| A32 | US- 7 737 156 | | 05-11-2006 | BOSS ET AL. | |
| A33 | US-2006 0111372 | | 05-25-2006 | HENDRIX ET AL. | |
| A34 | US- 2007 037977 | | 02-15-2007 | BELLEAU ET AL. | |

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1. ⁶ If present, enter. ⁷ Applicant is to place a checkmark here if English language translation is available. ⁸ This collection of information is required by 37 CFR 1.37 and 1.38. The information will be used to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/556,224 |
| Filing Date | September 27, 2006 |
| First Named Inventor | Martin Hendrix et al. |
| Art Unit | 1624 |
| Examiner Name | Susanna Moore |
| Attorney Docket Number | 01-2116 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
| B1 | | GB-937 724 | 09-25-1963 | CIBA LTD | | |
| B2 | | DE-1 156 415 | 10-31-1963 | CIBA GEIGY | | C22 |
| B3 | | EP-0 286 028 | 10-12-1988 | BOEHRINGER MANNHEIM GMBH | | B57 |
| B4 | | DE-4 004 558 | 09-27-1990 | SANYO KOKUSAKU POLY CO | | A10 |
| B5 | | EP- 496 617 | 07-29-1992 | GENSIA PHARMA | | |
| B6 | | WO-94 14802 | 07-07-1994 | BELLEAU PIERRETTE & HF | | |
| B7 | | WO-94 17803 | 08-18-1994 | GENSIA INC. | | |
| B8 | | EP-0 826 387 | 11-30-1994 | CIBA GEIGY AG | | |
| B9 | | EP-0 679 657 | 11-02-1995 | CIBA GEIGY AG | | A9 |
| B10 | | WO-96 28429 | 09-19-1996 | SANOFI WINTHROP INC | | |
| B11 | | WO-97 16456 | 05-09-1997 | CHONG KUN DANG CORP | | |
| B12 | | WO-97 46569 | 12-11-1997 | CIBA GEIGY AG | | |
| B13 | | WO-98 00434 | 01-08-1998 | CIBA GEIGY AG | | |
| B14 | | WO-98 16184 | 04-23-1998 | ICON PHARMACEUTICALS | | |
| B15 | | JP-11 501923 | 02-16-1999 | INCYTE PHARMA INC | | |
| B16 | | CA-2 357 146 | 07-13-2000 | USTAV EX BOTAN AKADEMIE VED CE | | |
| B17 | | WO-2000 043394 | 07-27-2000 | NPS ALLELIX CORP | | |
| B18 | | WO-2001 05758 | 01-25-2001 | HENKEL KGAA | | C21 |
| B19 | | WO-2001 06035 | 01-25-2001 | BAYER AG | | A16 |
| B20 | | JP-2001 514638 | 09-11-2001 | INOTEK CORP | | |
| B21 | | WO-2001 077075 | 10-18-2001 | ASTRAZENECA AB | | |
| B22 | | WO-2002 16348 | 02-28-2002 | MERCK & CO INC | | |
| B23 | | WO-2002 057425 | 07-25-2002 | | | |
| B24 | | JP-2002 523507 | 07-30-2002 | | | A22 |
| B25 | | WO-2002 074774 | 09-26-2002 | PFIZER LTD | | |
| B26 | | WO-2002 086180 | 10-31-2002 | mitsubishi RAYON CO | | A27 |
| B27 | | WO-2003 022859 | 03-20-2003 | EPOCH BIOSCIENCES INC | | |
| B28 | | WO-2003 037432 | 05-08-2003 | PFIZER PROD INC | | |
| B29 | | CA 2 466 824 | 05-08-2003 | PFIZER | | |
| B30 | | WO-2003 072757 | 09-04-2003 | BIOTA INC | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (e.g., WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year when the patent right is granted is made in the first column of the right margin of the document, and of the month in the second column, by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/556,224 |
| Filing Date | September 27, 2006 |
| First Named Inventor | Martin Hendrix et al. |
| Art Unit | 1624 |
| Examiner Name | Susanna Moore |
| Attorney Docket Number | 01-2116 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² – Number ³ – Kind Code ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
| | B31 | WO-2003 099840 | 12-04-2003 | ISIS PHARMACEUTICALS INC | | |
| | B32 | WO-2004 002999 | 01-08-2004 | IDENIX CAYMAN LTD | | |
| | B33 | DE-102 38 722 | 03-11-2004 | BAYER AG | | A32 |
| | B34 | WO-2004 046331 | 06-03-2004 | IDENIX CAYMAN LTD | | |
| | B35 | EP-1 460 077 | 09-22-2004 | JORDANIAN PHARMACEUTICAL MFG | | |
| | B36 | JP-2004 536933 | 12-09-2004 | PPG IND OHIO INC | | B58 |
| | B37 | WO-2004 108139 | 12-16-2004 | AREXIS AB | | |
| | B38 | WO-2005 051944 | 06-09-2005 | UNIV CONNECTICUT | | |
| | B39 | JP-2005 531549 | 10-20-2005 | | | A31 |
| | B40 | JP-2006 501272 | 01-12-2006 | BOEHRINGER INGELHEIM INT | | A32 |
| | B41 | JP-2006 503051 | 01-26-2006 | | | |
| | B42 | WO-2006 076455 | 07-20-2006 | ARENA PHARM INC | | |
| | B43 | WO-2006 084281 | 08-10-2006 | MILLENNIUM PHARM INC | | |
| | B44 | WO-2006 091905 | 08-31-2006 | GILEAD SCIENCES INC | | |
| | B45 | WO-2006 125548 | 11-30-2006 | BAYER HEALTHCARE AG | | C20 |
| | B46 | WO-2007 025043 | 03-01-2007 | IDENIX PHARMACEUTICALS INC | | |
| | B47 | WO-2007 046747 | 04-26-2007 | ASTRAZENECA AB | | |
| | B48 | WO-2008 005542 | 01-10-2008 | GILEAD SCIENCES INC | | |
| | B49 | WO-2008 055959 | 05-15-2008 | GALAPAGOS NV | | |
| | B50 | WO-2008 100447 | 08-21-2008 | GILEAD SCIENCES INC | | |
| | B51 | WO-2008 104077 | 09-04-2008 | METHYLCENE INC | | |
| | B52 | WO-2008 139293 | 11-20-2008 | Pfizer | | |
| | B53 | WO-2009 068617 | 06-04-2009 | BOEHRINGER INGELHEIM INT | | |
| | B54 | WO-2009 121919 | 10-08-2009 | BOEHRINGER INGELHEIM INT | | |
| | B55 | WO-2010 026214 | 03-11-2010 | BOEHRINGER INGELHEIM INT | | |
| | B56 | WO-2010 112437 | 10-07-2010 | BOEHRINGER INGELHEIM INT | | |

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant. **Applicant's unique citation designation number (optional). See Kinds of Patent USPTO Patent Documents at www.uspto.gov/patent/step/001-04. *After Office has issued the document, by the two-letter code (e.g., WO, PCT, Standard 16, etc.). For Japanese patent documents, the indicator of the year of the issue of the document and the serial number of the patent document. *Kinds of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. **Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the required application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/556,224 |
| Filing Date | September 27, 2006 |
| First Named Inventor | Martin Hendrix et al. |
| Art Unit | 1624 |
| Examiner Name | Susanna Moore |
| Attorney Docket Number | 01-2116 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
| | | Country Code ² – Number ³ – Kind Code ⁴ (if known) | | | | |
| | B57 | CA-1 311 201 | 12-08-1992 | BOEHRINGER MANNHEIM GMBH | ENG | |
| | B58 | WO-2003 011925 | 02-13-2003 | PPG IND OHIO INC | ENG | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | C1 | Accessed on December 18, 2008, http://en.wikipedia.org/wiki/Armenia | |
| | C2 | Accessed on December 18, 2008, www.mentalhealth.org.uk/information/mental-health-a-z/dementia | |
| | C3 | BARGER ET AL., Journal of Neurochemistry, 1995, Vol. 64, No. 5, pp. 2087-2096 | |
| | C4 | BRYN ET AL., Solid State Chemistry of Drugs, 1999, Vol. 2, No. 10, pp. 232-247 | |
| | C5 | Chemical Abstract Service, Database Chemcats, 2007, Database Accession No. ALB-H01677136, XP002556309 | |
| | C6 | FRANCIS ET AL., International Journal of Geriatric Psych., 2003, Vol. 18, pp. S15-21 | |
| | C7 | FRANCIS ET AL., Journal of Neurochemistry, 1993, Vol. 60, No. 5, pp. 1589-1604 | |
| | C8 | HARB ET AL., Chemical Papers, 2005, Vol. 159, No. 3, pp. 187-195 | |
| | C9 | HUNG ET AL., Journal of Organic Chemistry, 1981, Vol. 46, pp. 5413-5414 | |
| | C10 | Last accessed July 15, 2010, http://www.ncbi.nlm.nih.gov/medlineplus/ency/article/000746.htm | |
| | C11 | MARKWALDER, J. A. ET AL., Journal of Medicinal Chemistry, 2004, Vol. 47, pp. 5894-5911, XP002399637 | |
| | C12 | PRICKAERTS ET AL., Neuroscience, 2002, Vol. 113, pp. 351-361 | |
| | C13 | PUZZO ET AL., Journal of Neuroscience, 2005, Vol. 25, No. 29, pp. 6887-6897 | |

| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|
| | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reexamination is required. It is recommended to provide the date of the reexamination in the same manner as the date of the original patent application. ⁵Kind of document by the appropriate symbols as indicated on the document under "Kind of Document" (16 if available). ⁶Applicable to patent applications filed on or after November 29, 2001. ⁷See 37 CFR 1.14.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be paid by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/556,224 |
| Filing Date | September 27, 2006 |
| First Named Inventor | Martin Hendrix et al. |
| Art Unit | 1624 |
| Examiner Name | Susanna Moore |
| Attorney Docket Number | 01-2116 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | C14 | REYMANN ET AL., <i>Neuropharmacology</i> , 2007, Vol. 52, pp. 24-40 | |
| | C15 | SCHMIDT ET AL., "Pyrazolo[3,4-d]pyrimidin-nucleoside," <i>Chemische Berichte</i> , 1977, Vol. 110, pp. 2445-2455 | |
| | C16 | TIMBERLAKE ET AL., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups," <i>Patai</i> , 1975, Chapter 4 | |
| | C17 | UGARKAR ET AL., <i>Journal of Medicinal Chemistry</i> , 1984, Vol. 27, No. 8, pp. 1026-1030 | |
| | C18 | VAN STAVEREN ET AL., <i>Journal of Neurocytology</i> , 2002, Vol. 31, pp. 729-741 | |
| | C19 | WANG ET AL., <i>Gene</i> , 2003, Vol. 314, pp. 15-27 | |
| | C20 | THOMSON INNOVATION RECORD VIEW, Publication Date: November 30, 2006, English Translation of Description and Claims for WO2006125548 | |
| | C21 | THOMSON INNOVATION RECORD VIEW, Publication Date: January 25, 2001, English Translation of Description and Claims for WO-2001 006035 | |
| | C22 | THOMSON INNOVATION RECORD VIEW, Publication Date: October 31, 1963, English Translation of Description and Claims for DE 1 156 415 | |

| Examiner Signature | Date Considered | |
|--|--------------------|--|
| EXAMINER Initials if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Initials of the form with next communication to appear. * Applicant's unique citation number, not publication number. See Kind Codes of USPTO Patents and Documents at www.uspto.gov or MPEP 801.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached. | | |

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is provided by 35 U.S.C. 122. Collection is estimated to require 2 hours to complete. During gathering, preparing, and authoring the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or amount of time required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2